|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1990-5-16
|
|
pubmed:abstractText |
The efficacy of a new class of drugs for Pneumocystis carinii pneumonitis was demonstrated. 566C80, a hydroxynaphthoquinone, administered orally in a dose of greater than or equal to 100 mg/kg of body weight per day prophylactically prevented P. carinii pneumonitis in 90% or more of rats, while all untreated control animals developed pneumonitis. When 566C80 (100 mg/kg per day) was administered for 3 weeks after P. carinii pneumonitis was established, therapy was totally effective and all of the untreated controls had progressive P. carinii pneumonitis. A dose of 566C80 of between 25 and 50 mg/kg per day protected 50% of the rats from P. carinii pneumonitis, and a dose of between 50 and 100 mg/kg per day cured 50% of those treated for P. carinii pneumonitis. Both prophylaxis and treatment with 566C80 were at least as effective as with trimethoprim-sulfamethoxazole. Animals maintained on immunosuppression after completion of treatment remained free of P. carinii, suggesting a killing effect. Clearance of P. carinii was associated with levels of 60 micrograms or more of 566C80 per ml of plasma. This hydroxynaphthoquinone offers promise as an anti-P. carinii drug.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-205176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-315754,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-33002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-367298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-3920634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-412099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-4365115,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-6037033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-6331460,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-702049,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2327770-934316
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
225-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2327770-Animals,
pubmed-meshheading:2327770-Anti-Infective Agents,
pubmed-meshheading:2327770-Atovaquone,
pubmed-meshheading:2327770-Dexamethasone,
pubmed-meshheading:2327770-Lung,
pubmed-meshheading:2327770-Male,
pubmed-meshheading:2327770-Naphthoquinones,
pubmed-meshheading:2327770-Pneumonia, Pneumocystis,
pubmed-meshheading:2327770-Rats,
pubmed-meshheading:2327770-Rats, Inbred Strains,
pubmed-meshheading:2327770-Tetracyclines,
pubmed-meshheading:2327770-Trimethoprim-Sulfamethoxazole Combination
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.
|
|
pubmed:affiliation |
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
|
|
pubmed:publicationType |
Journal Article
|
